Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment

• Published in: PloS one Vol. 17; no. 9; p. e0274181
• Main Authors: Takei, Satomi, Ai, Tomohiko, Yamamoto, Takamasa, Igawa, Gene, Kanno, Takayuki, Tobiume, Minoru, Hiki, Makoto, Saito, Kaori, Khasawneh, Abdullah, Wakita, Mitsuru, Misawa, Shigeki, Miida, Takashi, Okuzawa, Atsushi, Suzuki, Tadaki, Takahashi, Kazuhisa, Naito, Toshio, Tabe, Yoko
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 15.09.2022; Public Library of Science (PLoS)
• Subjects: Antibodies; Anticoagulants; Antiviral agents; Antiviral drugs; Assaying; Biology and Life Sciences; Coronaviruses; Correlation; COVID-19; Evaluation; FDA approval; Health aspects; Immune status; Immunoassay; Immunoassays; Medicine and Health Sciences; Neutralization; Neutralizing; Patients; Performance evaluation; Proteins; Regression analysis; Research and Analysis Methods; Serology; Serum; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Vaccines; Viral antibodies; Viral diseases; Viruses; Japan; United States > US; Switzerland

Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S...